Zhao J J, Liu F L
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Zhonghua Wei Chang Wai Ke Za Zhi. 2022 Feb 25;25(2):114-119. doi: 10.3760/cma.j.cn441530-20211103-00446.
The proportion of adenocarcinoma of the esophagogastric junction (AEG) in gastric cancer is gradually increasing. Due to the unique anatomical structure and biological characteristics of the tumor at this site, AEG has a certain degree of complexity in many aspects of diagnosis and treatment, which brings difficulties to the operation method, the selection of the resection range, the lymph node dissection and the treatment decision-making. Therefore, AEG has always been the focus of academic debate. With the development of minimally invasive surgery in recent years, laparoscopic technology has been increasingly mature and widely used in the treatment of gastrointestinal tumors. Compared with distal gastric cancer, the minimally invasive treatment of AEG is in a lagging state, and there are also a series of problems that have not yet reached a consensus. This article reviews and summarizes the recent research progress in two aspects: proximal gastrectomy for AEG and lymph node dissection. Laparoscopic-assisted proximal gastrectomy is safe for early proximal gastric cancer and has a long-term survival outcome not inferior to total gastrectomy, but the surgical indications must be strictly selected. Abdominal lymph node metastasis of AEG is mainly in group 1, 2, 3, and 7, and mediastinal lymph node metastasis is closely related to the length of the infiltrated esophagus. The abdominal transhiatal (TH) approach can obtain a sufficient number of harvested lymph node, and has good safety and efficacy, which is the first-choice of surgical approach for early AEG. The results of the CLASS-10 clinical trial can provide a higher level of evidence for laparoscopic mediastinal lymph node dissection. Laparoscopic surgery for AEG should be carried out in experienced medical center based on clinical research.
胃癌中食管胃交界腺癌(AEG)的比例正在逐渐上升。由于该部位肿瘤独特的解剖结构和生物学特性,AEG在诊断和治疗的诸多方面都具有一定程度的复杂性,这给手术方式、切除范围的选择、淋巴结清扫以及治疗决策带来了困难。因此,AEG一直是学术争论的焦点。近年来,随着微创手术的发展,腹腔镜技术日益成熟并广泛应用于胃肠道肿瘤的治疗。与远端胃癌相比,AEG的微创治疗处于滞后状态,且存在一系列尚未达成共识的问题。本文对AEG近端胃切除术和淋巴结清扫这两个方面的近期研究进展进行综述和总结。腹腔镜辅助近端胃切除术对早期近端胃癌是安全的,其长期生存结果不逊于全胃切除术,但手术适应证必须严格选择。AEG的腹部淋巴结转移主要在第1、2、3和7组,纵隔淋巴结转移与食管浸润长度密切相关。经腹食管裂孔(TH)入路能够获取足够数量的清扫淋巴结,且安全性和有效性良好,是早期AEG手术入路的首选。CLASS - 10临床试验结果可为腹腔镜纵隔淋巴结清扫提供更高水平的证据。AEG的腹腔镜手术应在经验丰富的医学中心基于临床研究开展。